Cargando...
Measuring Cardiopulmonary Complications of Carfilzomib Treatment and Associated Risk Factors Using the SEER-Medicare Database
BACKGROUND. Carfilzomib improves survival in patients with relapsed myeloma. Given the strict eligibility criteria in the clinical trials, the actual frequency of cardiac (CAEs) and pulmonary adverse events (PAEs) and risk factors associated with these AEs in the general population needs to be estab...
Gardado en:
| Publicado en: | Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6992490/ https://ncbi.nlm.nih.gov/pubmed/31721140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32601 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|